2023-503985-21-00RecruitingPhase 1
Performance and prognostic value of 68Ga-FAPI PET/CT in non-small cell lung cancer (NSCLC)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Jun 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 May 2023
- Start date
- 7 Nov 2023
- Lead sponsor
- Meander Medisch Centrum
- Diseases
- Lung cancer
- EU CT number
- 2023-503985-21-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer. It studies how well a 68Ga-FAPI PET/CT scan works and what it can tell about the course of the disease.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Non-small cell lung cancer. The record does not give a stage.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Meander Medical Center | Amersfoort | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.